钠–葡萄糖协同转运蛋白2抑制剂与心力衰竭患者交感神经功能的研究进展

Research Progress on Sodium-Dependent Glucose Transporters 2 Inhibitors and Sym-pathetic Nerve Function in Patients with Heart Failure

交感神经(SNS)过度兴奋是导致心力衰竭发生发展的重要机制之一。钠–葡萄糖协同转运蛋白2 (SGLT2)抑制剂是治疗心力衰竭的新型药物,近来研究发现,SGLT2抑制剂可以通过降低心力衰竭患者SNS的功能来使心血管获益。本文着重从SGLT2i对于心力衰竭的获益及机制进行综述,以提高临床工作者在心力衰竭治疗中对SGLT2抑制剂与交感神经关系的认识。

Sympathetic nervous system (SNS) hyperexcitation is one of the important mechanisms leading to the development of heart failure. Sodium-dependent glucose transporters 2 (SGLT2) inhibitors are novel drugs for the treatment of heart failure, and recent studies have found that SGLT2 inhibitors can confer cardiovascular benefits by reducing the function of SNS in patients with heart failure. This article focuses on the benefits and mechanisms of SGLT2i in heart failure, so as to improve the understanding of the relationship between SGLT2 inhibitors and sympathetic nerves in the treat-ment of heart failure.